Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Immune Monitoring in a Phase 1 Trial of a PSA DNA Vaccine in Patients with Hormone-Refractory Prostate Cancer
Ashley M. Miller, Volkan Özenci, Rolf Kiessling, et al.
Journal of Immunotherapy (2005) Vol. 28, Iss. 4, pp. 389-395
Closed Access | Times Cited: 74

Showing 1-25 of 74 citing articles:

DNA vaccines: precision tools for activating effective immunity against cancer
Jason Rice, Christian H. Ottensmeier, Freda K. Stevenson
Nature reviews. Cancer (2008) Vol. 8, Iss. 2, pp. 108-120
Closed Access | Times Cited: 413
A randomized phase II study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen-independent prostate cancer.
Philip M. Arlen, James L. Gulley, Catherine Parker, et al.
Clinical Cancer Research (2006) Vol. 12, Iss. 4, pp. 1260-1269
Open Access | Times Cited: 292
Effect of Plasmid DNA Vaccine Design and In Vivo Electroporation on the Resulting Vaccine-Specific Immune Responses in Rhesus Macaques
Amara Luckay, Maninder K. Sidhu, Rune Kjeken, et al.
Journal of Virology (2007) Vol. 81, Iss. 10, pp. 5257-5269
Open Access | Times Cited: 206
Electroporation for the Delivery of DNA-based Vaccines and Immunotherapeutics: Current Clinical Developments
Angela M. Bodles-Brakhop, Richard Heller, Ruxandra Draghia‐Akli
Molecular Therapy (2009) Vol. 17, Iss. 4, pp. 585-592
Open Access | Times Cited: 201
DNA Vaccines: Developing New Strategies against Cancer
Daniela Piergili Fioretti, Sandra Iurescia, Vito Michele Fazio, et al.
Journal of Biomedicine and Biotechnology (2010) Vol. 2010, pp. 1-16
Open Access | Times Cited: 199
Trial Watch: DNA vaccines for cancer therapy.
Laura Senovilla, Erika Vacchelli, Pauline Garcia, et al.
Europe PMC (PubMed Central) (2014) Vol. 3, Iss. 1, pp. e28185-e28185
Open Access | Times Cited: 106
Beyond the biomarker role: prostate-specific antigen (PSA) in the prostate cancer microenvironment
Afshin Moradi, Srilakshmi Srinivasan, Judith A. Clements, et al.
Cancer and Metastasis Reviews (2019) Vol. 38, Iss. 3, pp. 333-346
Closed Access | Times Cited: 87
DNA Vaccines: Recent Developments and Future Possibilities
Margaret A. Liu, Britta Wahrén, Gunilla B. Karlsson Hedestam
Human Gene Therapy (2006) Vol. 17, Iss. 11, pp. 1051-1061
Closed Access | Times Cited: 136
Vaccination of hormone‐refractory prostate cancer patients with peptide cocktail‐loaded dendritic cells: Results of a phase I clinical trial
Susanne Fuessel, Axel Meye, Marc Schmitz, et al.
The Prostate (2006) Vol. 66, Iss. 8, pp. 811-821
Closed Access | Times Cited: 124
DNA vaccines to attack cancer: Strategies for improving immunogenicity and efficacy
Angeliki Tiptiri-Kourpeti, Katerina Spyridopoulou, Aglaia Pappa, et al.
Pharmacology & Therapeutics (2016) Vol. 165, pp. 32-49
Closed Access | Times Cited: 80
Trial watch
Laura Senovilla, Erika Vacchelli, Pauline Garcia, et al.
OncoImmunology (2013) Vol. 2, Iss. 4, pp. e23803-e23803
Open Access | Times Cited: 78
DNA vaccine coding for the rhesus prostate specific antigen delivered by intradermal electroporation in patients with relapsed prostate cancer
Fredrik Eriksson, Thomas H. Tötterman, Anna-Karin Maltais, et al.
Vaccine (2013) Vol. 31, Iss. 37, pp. 3843-3848
Closed Access | Times Cited: 65
DNA vaccines for prostate cancer
Christopher D. Zahm, Viswa T. Colluru, Douglas G. McNeel
Pharmacology & Therapeutics (2017) Vol. 174, pp. 27-42
Open Access | Times Cited: 53
Recent advances in strategies for immunotherapy of human papillomavirus‐induced lesions
Shreya Kanodia, Diane M. Da Silva, W. Martin Kast
International Journal of Cancer (2007) Vol. 122, Iss. 2, pp. 247-259
Open Access | Times Cited: 72
Cancer immunotherapy based on recombinant Salmonella enterica serovar Typhimurium aroA strains secreting prostate-specific antigen and cholera toxin subunit B
Joachim Fensterle, Birgit Bergmann, Clarisse L. R. P. Yone, et al.
Cancer Gene Therapy (2007) Vol. 15, Iss. 2, pp. 85-93
Open Access | Times Cited: 66
Kallikrein-related peptidases: bridges between immune functions and extracellular matrix degradation
Georgia Sotiropoulou, Georgios Pampalakis
Biological Chemistry (2010) Vol. 391, Iss. 4
Closed Access | Times Cited: 61
Preclinical and clinical development of DNA vaccines for prostate cancer
Viswa T. Colluru, Laura E. Johnson, Brian M. Olson, et al.
Urologic Oncology Seminars and Original Investigations (2013) Vol. 34, Iss. 4, pp. 193-204
Open Access | Times Cited: 48
Advances in Micro/Nano Electromechanical Systems and Fabrication Technologies
Kenichi Takahata
InTech eBooks (2013)
Open Access | Times Cited: 46
Kallikrein-related peptidases (KLKs) as emerging therapeutic targets: focus on prostate cancer and skin pathologies
Margaritis Avgeris, Andreas Scorilas
Expert Opinion on Therapeutic Targets (2016) Vol. 20, Iss. 7, pp. 801-818
Closed Access | Times Cited: 43
mRNA vaccines for prostate cancer: A novel promising immunotherapy
Yaxiong Tang, Xianyanling Yi, Jianzhong Ai
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer (2025), pp. 189333-189333
Closed Access
Enhancing cancer vaccines with immunomodulators
Neil L. Berinstein
Vaccine (2007) Vol. 25, pp. B72-B88
Closed Access | Times Cited: 56
A novel IgE antibody targeting the prostate-specific antigen as a potential prostate cancer therapy
Tracy R. Daniels‐Wells, Gustavo Helguera, Richard K. Leuchter, et al.
BMC Cancer (2013) Vol. 13, Iss. 1
Open Access | Times Cited: 44
Systemic GM-CSF Recruits Effector T Cells into the Tumor Microenvironment in Localized Prostate Cancer
Xiao X. Wei, Stephen Chan, Serena S. Kwek, et al.
Cancer Immunology Research (2016) Vol. 4, Iss. 11, pp. 948-958
Open Access | Times Cited: 33
Immunization with recombinant DNA and modified vaccinia virus Ankara (MVA) vectors delivering PSCA and STEAP1 antigens inhibits prostate cancer progression
Magdalena Krupa, Marta Cañamero, Carmen Gómez, et al.
Vaccine (2010) Vol. 29, Iss. 7, pp. 1504-1513
Closed Access | Times Cited: 42
Towards progress on DNA vaccines for cancer
Devin B. Lowe, Michael H. Shearer, Cynthia Jumper, et al.
Cellular and Molecular Life Sciences (2007) Vol. 64, Iss. 18, pp. 2391-2403
Open Access | Times Cited: 43
Page 1 - Next Page

Scroll to top